Sanofi American Depositary Receipt (SNY)
Sanofi plans to change hospital drug-discount program, WSJ reports
French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income and uninsured patients, the Wall Street Journal reported on Friday.
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse drug portfolio and a robust pipeline of future drugs to market, this big pharma brand will play a major role in treatments in the next decades to come. The stock currently offers a 4% dividend yield, while trading below its moving average and with a mixed valuation picture vs key peers.
SandboxAQ CEO on the firm's partnership with Sanofi
Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical development.
Why Sanofi Stock Flew Higher on Friday
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Sanofi (NASDAQ:SNY ) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Thomas Kudsk - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research and Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Brendan O'Callaghan - Executive Vice President, Manufacturing and Supply Roy Papatheodorou - Executive Vice President, General Counsel Conference Call Participants Richard Vosser - JPMorgan Emily Field - Barclays Graham Parry - BofA Seamus Fernandez - Guggenheim Jo Walton - UBS Peter Welford - Jefferies Luisa Hector - Berenberg Thibault Boutherin - Morgan Stanley Simon Baker - Redburn Steve Scala - TD Cowen David Risinger - Leerink Richard Parkes - BNP Exane Rajesh Kumar - HSBC Eric Berrigaud - Stifel Florent Cespedes - Bernstein Thomas Kudsk Welcome to the Q3 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com.
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.
Sanofi CEO Paul Hudson on Q3 results: The modernization effort is starting to pay off
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the company's Dupixent drug, and more.
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
On Friday, Sanofi SA SNY reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency.
